INTRODUCTION: Malignant pheochromocytomas (PCCs) and paragangliomas (PGLs) are rare disorders arising from the adrenal gland, from the glomera along parasympathetic nerves or from paraganglia along the sympathetic trunk. According to the WHO classification, malignancy of PCCs and PGLs is defined by the presence of metastases at non-chromaffin sites distant from that of the primary tumor and not by local invasion. The overall prognosis of metastasized PCCs/PGLs is poor. Surgery offers currently the only change of cure. Preferably, the discrimination between malignant and benign PCCs/PGLs should be made preoperatively. METHODS: This review summarizes our current knowledge on how benign and malignant tumors can be distinguished. CONCLUSION: Due to the rarity of malignant PCCs/PGLs and the obvious difficulties in distinguishing benign and malignant PCCs/PGLs, any patient with a PCC/PGL should be treated in a specialized center where a multidisciplinary setting with specialized teams consisting of radiologists, endocrinologist, oncologists, pathologists and surgeons is available. This would also facilitate future studies to address the existing diagnostic and/or therapeutic obstacles.
INTRODUCTION:Malignant pheochromocytomas (PCCs) and paragangliomas (PGLs) are rare disorders arising from the adrenal gland, from the glomera along parasympathetic nerves or from paraganglia along the sympathetic trunk. According to the WHO classification, malignancy of PCCs and PGLs is defined by the presence of metastases at non-chromaffin sites distant from that of the primary tumor and not by local invasion. The overall prognosis of metastasized PCCs/PGLs is poor. Surgery offers currently the only change of cure. Preferably, the discrimination between malignant and benign PCCs/PGLs should be made preoperatively. METHODS: This review summarizes our current knowledge on how benign and malignant tumors can be distinguished. CONCLUSION: Due to the rarity of malignant PCCs/PGLs and the obvious difficulties in distinguishing benign and malignant PCCs/PGLs, any patient with a PCC/PGL should be treated in a specialized center where a multidisciplinary setting with specialized teams consisting of radiologists, endocrinologist, oncologists, pathologists and surgeons is available. This would also facilitate future studies to address the existing diagnostic and/or therapeutic obstacles.
Authors: U Plöckinger; G Rindi; R Arnold; B Eriksson; E P Krenning; W W de Herder; A Goede; M Caplin; K Oberg; J C Reubi; O Nilsson; G Delle Fave; P Ruszniewski; H Ahlman; B Wiedenmann Journal: Neuroendocrinology Date: 2005-04-18 Impact factor: 4.914
Authors: W W de Herder; D J Kwekkeboom; R Valkema; R A Feelders; M O van Aken; S W J Lamberts; A J van der Lely; E P Krenning Journal: J Endocrinol Invest Date: 2005 Impact factor: 4.256
Authors: Weng Onn Lui; Jindong Chen; Sven Gläsker; Bernhad U Bender; Casey Madura; Sok Kean Khoo; Eric Kort; Catharina Larsson; Harmut P H Neumann; Bin Tean Teh Journal: Oncogene Date: 2002-02-07 Impact factor: 9.867
Authors: Bas Havekes; Kathryn King; Edwin W Lai; Johannes A Romijn; Eleonora P M Corssmit; Karel Pacak Journal: Clin Endocrinol (Oxf) Date: 2009-06-08 Impact factor: 3.478
Authors: David J Pinato; James R M Black; Ramya Ramaswami; Tricia M Tan; Delali Adjogatse; Rohini Sharma Journal: Med Oncol Date: 2016-04-08 Impact factor: 3.064
Authors: David Taïeb; Alexandre Kaliski; Carsten C Boedeker; Victoria Martucci; Tito Fojo; John R Adler; Karel Pacak Journal: Endocr Rev Date: 2014-07-17 Impact factor: 19.871
Authors: Dhaval Patel; Amit Mehta; Naris Nilubol; William Dieckmann; Karel Pacak; Electron Kebebew Journal: Ann Surg Date: 2016-03 Impact factor: 12.969
Authors: Hilary C McCrary; Eric Babajanian; Matias Calquin; Patrick Carpenter; Geoffrey Casazza; Anne Naumer; Samantha Greenberg; Wendy Kohlmann; Richard Cannon; Marcus M Monroe; Jason P Hunt; Luke Buchmann Journal: JAMA Otolaryngol Head Neck Surg Date: 2019-07-01 Impact factor: 6.223
Authors: Peter Igaz; Ivan Igaz; Zoltán Nagy; Gábor Nyírő; Peter M Szabó; András Falus; Attila Patócs; Károly Rácz Journal: Cell Mol Life Sci Date: 2014-10-09 Impact factor: 9.261
Authors: Wenche Sjursen; Henrik Halvorsen; Eva Hofsli; Siri Bachke; Asa Berge; Lars F Engebretsen; Sture E Falkmer; Ursula G Falkmer; Jan E Varhaug Journal: Fam Cancer Date: 2013-09 Impact factor: 2.375